pharmacokinetics, pyridoxine, pyridoxal-5'-phosphate
Conditions
Interventions
daily intake of 50 mg of pyridoxal-s'-phosphate or 50 mg pyridoxine (active control) during 7 days
Sponsors
Maastricht University, MUMC
Eligibility
Inclusion criteria
Inclusion criteria: healthy, adults, both male and female, aged between 20 and 50 years with normal liver and kidney function, with normal BMI (between 19 and 25), and able to come to the research laboratory on 3 specified occasions within a one week period
Exclusion criteria
Exclusion criteria: use of medication (with the exception of oral contraceptives), use of vitamin supplements during the past 6 months, detectable plasma level of pyridoxine, non-normal liver and kidney functions, BMI 25, alcohol consumption > 2 drinks/day
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| plasma pyridoxine concentration during 4 h after the first inake (pharmacokinetics, AUC), and at days 3 and 7 of the study | — |
Secondary
| Measure | Time frame |
|---|---|
| vitamin B6 vitamers and metabolites such as pyridoxal, pyridoxal-5'-phospate, pyridoxamine, 4-pyridoxic acid | — |
Contacts
Public ContactGeja J. Hageman
Dept. of Pharmacology and Toxicology, Maastricht University, P.O. Box 616,
Outcome results
None listed